Patients with non-small cell lung cancer and the AT genotype may be at a decreased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.